Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q4 FY2021 Earnings Presentation
30 slides from Dr. Lal Pathlabs's earnings presentation, May 21, 2021
Slide 1: Exchange filing cover letter
May 21, 2021 The National Stock Exchange of India Limited The Bombay Stock Exchange Limited Exchange Plaza 15th Floor, Phiroze Jeejeeboy Towers Bandra Kurla Complex, Bandra (E) Dalal Street, Mumbai - 400051 Mumbai – 400001 Subject: Earnings Presentation on Audited Financial Results (Standalone and C
Slide 2: Q4 FY21 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q4 FY21 Results Presentation May 21, 2021
Slide 3: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the “Company”) for use in presentat
Slide 4: Q4 FY21 Snapshot
Q4 FY21 Snapshot 42.9% 101.7% 161.0% INR 431.0 Cr INR 129.5 Cr INR 85.1 Cr Revenues Normalised EBITDA PAT 33.3% 34.7% ~ 5.9 mn 15.1 mn ~ Patients Samples Q4 FY21 is not comparable to Q4 FY20 due to Nationwide lock-down in March 2020 3
Slide 5: Table of Contents
Table of Contents Dr. Lal PathLabs – At a Glance 5 Overview of Dr. Lal PathLabs 6 Key Performance Highlights 8 Financials 9 Financial Highlights 10 Operating Highlights 12 Management Commentary 13 Vibrant Outlook 14 Corporate Overview 16 Shareholding 27 Contact Us 29 DISCLAIMER: This presentation ma
Slide 6: Dr. Lal PathLabs – At a Glance
Dr. Lal PathLabs – At a Glance India’s Leading & Trusted 15% 22% 200% Diagnostics Company Largest* 3 Year Revenue 3-Year PAT Equity Dividend CAGR CAGR for FY 20-21 diagnostics 70+ years of experience chain in the in the field of diagnostics country with ~86% Rs 985.9 Cr. PAN India ROCE Cash & Invest
Slide 7: Overview of Dr. Lal PathLabs
Overview of Dr. Lal PathLabs Established brand Pan-India integrated Varied Offerings Unique and successful coverage operating model 231 clinical labs (including National Reference Lab at Catalogue of 471 test panels, Scalable model integrated Established consumer Delhi and Regional Reference 2,590 p
Slide 8: COVID, COVID Allied & Non-COVID Revenue
COVID, COVID Allied & Non-COVID Revenue Rs. Cr. • Non-COVID business grew at a phenomenal 382 growth rate of 26.8% in Q4 FY21 347 355 • COVID portfolio contribution to total revenue declined to 11.2% in Q4 FY21 from 21.6% in 209 Q3 FY21 due to regulations on pricing of RT- PCR testing • COVID Allied
Slide 9: Key Performance Highlights
Key Performance Highlights During Q4 FY21: • Revenues enhanced by 42.9% Y-o-Y to Rs. 431.0 crore • Normalised EBITDA (after eliminating the impact of stock based compensation & CSR) came in at Rs. 129.5 crore • Profit After Tax at Rs. 85.1 crore, higher by 161% over same period last year • Final div
Slide 10: Financials
Financials Particulars (Rs. Cr.) Q4 FY21 Q4 FY20 Gr % FY21 FY20 Gr % Revenue 431.0 301.7 42.9% 1,581.3 1,330.4 18.9% Expenditure 309.0 244.4 1,145.0 986.8 EBITDA 122.0 57.3 112.9% 436.3 343.6 27.0% Stock based comp. & CSR cost 7.5 6.9 26.3 22.0 Normalised EBITDA 129.5 64.2 101.7% 462.6 365.6 26.5% N
Slide 11: Financial Highlights
Financial Highlights All figures in Rs. Crore +42.9% • In Q4 FY21, Revenue improved to Rs. 431.0 crore, higher by 42.9% Y-o-Y led by : 431.0 – 33.3% increase in volumes 301.7 – Growth in Non-COVID business and uptick in Revenue COVID testing volumes in March • Realisation per patient in Q4 FY21 stoo
Slide 12: Financial Highlights
Financial Highlights All figures in Rs. Crore +144.1% • PBT for Q4 FY21 stood at Rs. 110.8 crore as compared to 110.8 Rs. 45.4 crore reported in the same quarter last year, representing a growth of 144.1% PBT • Q4 FY21 PBT margin came in at 25.7% vs. 15.0% in the 45.4 corresponding quarter of last y
Slide 13: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs +38 +1,552 +3,623 193 200 216 231 3,705 9,247 3,095 6,426 6,995 2,153 2,569 5,624 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 No. of Patients (Mn) No. of Samples (Mn) +33% +43% 17.6 19.4 20.3 47.7 49.7 15.2 34.
Slide 14: Management Commentary
Management Commentary Commenting on the results announcement, (Hony) Brig. Dr. Arvind Lal, Executive Chairman “Even though the concluding quarter of FY21 was marked by the second wave of COVID-19 pandemic in India, we have ensured that our non-COVID business has shown growth. The COVID business star
Slide 15: Vibrant Outlook
Vibrant Outlook Strongly develop Rest of India geographies, through Regional Reference Labs and cluster city approach for attractive markets Target to grow Evaluate best fit inorganic Deeper Penetration within the ahead opportunities in South & West North, East & Central Indian of the markets indust
Slide 16: Leveraging digital to make life easier for patient
Leveraging digital to make life easier for patient Logistics Lab Operations Business Digital Lab e-Commerce Mobile app Automation Automation Continuity Plan • Self Registration • Online test / health • Test booking, view • Field Executive • Totally integrated • ‘Multi Site’ model Kiosk for patients
Slide 17: Corporate Overview
Corporate Overview 16
Slide 18: Vision, Mission & Values
Vision, Mission & Values VISION Customer First Be the most trusted healthcare partner, enabling healthier lives Ethics & Integrity VALUES Quality To be the undisputed market leader by providing accessible, affordable, timely and quality healthcare, Accountability diagnostics, applying insights and c
Slide 19: DLPL Strategy for future growth
DLPL Strategy for future growth 1 2 Strengthen Expansion in Existing Offering Operations Expand 4 3 management of Geographic hospital based expansion and clinical laboratories 18
Slide 20: DLPL Strategy for future growth
DLPL Strategy for future growth Expand management of hospital Strengthen Existing Operations Expansion in Offering Geographic expansion based and clinical laboratories Boosting quality & reliability Improve breadth of Tap incremental contracts for Focus city & cluster approach standards diagnostic t
Slide 21: Consistent investments in R&D
Consistent investments in R&D DSIR recognized In House R&D unit R&D Collaboration with marquee Successful commercialization of with an experienced team of institutions tests research scientists and doctors Jawaharlal Nehru University for development of diagnostics kit for detection of mycobacterium
Slide 22: Genevolve: The Genomics initiative
Genevolve: The Genomics initiative GENEVOLVE brings the dawn of a new era of Genomic testing! Genevolve: Genomics division focuses on Genetic testing Offers wide range of key tests related to Oncogenomics, Neurogenomics, Rare disease & Pre-natal/ Post-natal New Tests New Tie-ups ONCOPATH • Sperm DNA
Slide 23: In-house adoption of Digital Histopathology
In-house adoption of Digital Histopathology Opportunities created by Digital Histopathology Reporting of Digital Breast cancer Panels using AI based • Enhanced access to second algorithms opinion, synchronous review Digital Histopathology for of slides remote routine • Enhanced quality of report
Slide 24: Highest Quality Standards in the Industry
Highest Quality Standards in the Industry 100+ Quality Digitally enabled Real time quality Risk based improvement solutions control quality assurance meetings on a daily implemented for monitoring framework basis with the quality audits network partners and trainings Best in the Industry CAP Profici
Slide 25: Best in class Logistics and Supply Chain management
Best in class Logistics and Supply Chain management Real Real time time service sample monitoring tracking Control tower Real time Field Automated Cash Productivity Executive collection and route tracking process planning with clients visibility 24
Slide 26: Enhanced Customer Experience in Home Collection
Enhanced Customer Experience in Home Collection Auto Routing engine to dynamically allocate the booking to nearest available phlebotomist Real time slot confirmation Real time phlebo visibility to to patient the patient Variable model which grows ECG at home service with business volume launched in
Slide 27: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Bharath Uppiliappan Ved Prakash Goel Executive Chairman Managing Director Whole-time Director Chief Executive Officer Chief Financial Officer Shankha Banerjee Munender Soperna Rajat Kalra Manoj Garg Company Sec
Slide 28: Shareholding as of 31st March, 2021
Shareholding as of 31st March, 2021 29.6% FIIs, FPIS & Foreign Company 8.8% 55.2% Others Promoter and Promoter Group 6.4% Mutual Funds* *Mutual Funds includes Alternate Investment Funds as well 27
Slide 29: Key Awards & Recognition
Key Awards & Recognition Dr. Om Manchanda honoured ICICI Lombard & CNBC EY Entrepreneur of The Data Quest Technology VC Circle Healthcare and awarded as ‘Healthcare TV18 India Risk Year 2019 – Life Award 2015 – Excellence Summit 2013 – Best Personality of the Year, 2020’ Management Awards 2020 Scien
Slide 30: Contact Us
Contact Us About Dr. Lal PathLabs Limited (DLPL) Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests